Researchers from the molecular diagnostics firm said their screen could identify a range of variant types to boost the identification of at-risk couples.
Only three out of 10 sequencing workflows detected all variants in a synthetic reference sample, according to a study presented at ACMG.
The company's net loss climbed about 30 percent to $4.0 million for Q4 2017, and reached $19.4 million for the full year.
The company has highlighted the study as evidence that its test would outperform Roche's FDA-approved liquid biopsy assay if implemented in the clinic.
The company's test boasted strong sensitivity and specificity for a range of different alterations in clinical and contrived samples, particularly for low-allele frequencies.
At the San Antonio Breast Cancer Symposium, Myriad reported on the ability of its 86 SNP score to predict disease risk for the majority of women of European ancestry.
The companies will validate and commercialize the assay as a companion diagnostic to identify best responders to Morphotek's investigational ovarian cancer treatment.
The company has achieved even higher specificity than earlier data demonstrated, and is now building up its sales and marketing infrastructure for the planned launch of its lung cancer test.
The firm's Cxbladder Monitor test was shown to have a high negative predictive value compared to other commercially available urine diagnostic tests for bladder cancer.
The company plans to outlicense the assay, developed using a custom Affymetrix microarray, to an interested partner.
Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.
The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.
In Science this week: genetic overlap among many psychiatric disorders, and more.
The Economist writes that an increasing number of scientific journals don't do peer review.